{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T11:57:22Z","timestamp":1649073442320},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T00:00:00Z","timestamp":1294876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s00108-010-2782-3","type":"journal-article","created":{"date-parts":[[2011,1,11]],"date-time":"2011-01-11T09:58:27Z","timestamp":1294739907000},"page":"209-217","source":"Crossref","is-referenced-by-count":0,"title":["Moderne Therapie der chronisch myeloischen Leuk\u00e4mie"],"prefix":"10.1007","volume":"52","author":[{"given":"A.A.","family":"Leitner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,13]]},"reference":[{"key":"2782_CR1","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041\u20136051","journal-title":"J Clin Oncol"},{"key":"2782_CR2","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","volume":"98","author":"Bonifazi","year":"2001","unstructured":"Bonifazi F, Vivo A de, Rosti G et al (2001) Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98:3074\u20133081","journal-title":"Blood"},{"key":"2782_CR3","first-page":"100","volume":"56","author":"Buchdunger","year":"1996","unstructured":"Buchdunger E, Zimmermann J, Mett H et al (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100\u2013104","journal-title":"Cancer Res"},{"key":"2782_CR4","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","volume":"28","author":"Burchert","year":"2010","unstructured":"Burchert A, M\u00fcller MC, Kostrewa P et al (2010) Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 28:1429\u20131435","journal-title":"J Clin Oncol"},{"key":"2782_CR5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"key":"2782_CR6","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","volume":"458","author":"Essers","year":"2009","unstructured":"Essers MA, Offner S, Blanco-Bose WE et al (2009) IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458:904\u2013908","journal-title":"Nature"},{"key":"2782_CR7","doi-asserted-by":"crossref","unstructured":"Guilhot F, Preudhomme C, Guilhot J et al (2010) Significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with imatinib (IM) for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukaemia (CML) patients (pts): confirmatory results at 18 months of part 1 of the Spirit Phase III Randomized Trial of the French CML Group (FI LMC). N Engl J Med (in press)","DOI":"10.1182\/blood.V114.22.340.340"},{"key":"2782_CR8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850\u2013858","journal-title":"J Natl Cancer Inst"},{"key":"2782_CR9","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/sj.leu.2403006","volume":"17","author":"Hehlmann","year":"2003","unstructured":"Hehlmann R, Berger U, Pfirrmann M et al (2003) Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 17:1529\u20131537","journal-title":"Leukemia"},{"key":"2782_CR10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M; European LeukemiaNet (2007) Chronic myeloid leukemia. Lancet 370:342\u2013350","journal-title":"Lancet"},{"key":"2782_CR11","doi-asserted-by":"crossref","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S et al (2010) Tolerability-adapted imatinib 800\u00a0mg vs 400\u00a0mg vs 400\u00a0mg + IFN in newly diagnosed chronic myeloid leukemia. J Clin Oncol (in press)","DOI":"10.1200\/JCO.2010.32.0598"},{"key":"2782_CR12","doi-asserted-by":"crossref","unstructured":"Hehlmann R, Jung-Munkwitz S, Saussele S (2010) Treatment of chronic myeloid leukemia when imatinib fails. Expert Opin Pharmacother (in press)","DOI":"10.1517\/14656566.2011.533169"},{"key":"2782_CR13","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3324\/haematol.2008.001214","volume":"93","author":"Hehlmann","year":"2008","unstructured":"Hehlmann R, Saussele S (2008) Treatment of chronic myeloid leukemia in blast crisis. Haematologica 93:1765\u20131769","journal-title":"Haematologica"},{"key":"2782_CR14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28\u201337","journal-title":"Blood"},{"key":"2782_CR15","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270","journal-title":"N Engl J Med"},{"key":"2782_CR16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-642-01222-8_9","volume":"184","author":"Keller","year":"2010","unstructured":"Keller G, Schafhausen P, Br\u00fcmmendorf TH (2010) Bosutinib. Recent Results Cancer Res 184:119\u2013127","journal-title":"Recent Results Cancer Res"},{"key":"2782_CR17","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","volume":"26","author":"Khorashad","year":"2008","unstructured":"Khorashad JS, Lavallade H de, Apperley JF et al (2008) Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 26:4806\u20134813","journal-title":"J Clin Oncol"},{"key":"2782_CR18","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1200\/JCO.2009.26.4945","volume":"28","author":"Laneuville","year":"2010","unstructured":"Laneuville P, Dilea C, Yin OQ et al (2010) Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia. J Clin Oncol 28:e169\u2013e171","journal-title":"J Clin Oncol"},{"key":"2782_CR19","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"},{"key":"2782_CR20","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"Noens","year":"2009","unstructured":"Noens L, Lierde MA van, Bock R de et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:5401\u20135411","journal-title":"Blood"},{"key":"2782_CR21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","volume":"103","author":"O","year":"2004","unstructured":"O\u2019Dwyer ME, Mauro MJ, Blasdel C et al (2004) Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 103:451\u2013455","journal-title":"Blood"},{"key":"2782_CR22","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood.V114.22.862.862","volume":"114","author":"Pletsch","year":"2009","unstructured":"Pletsch N, Saussele S, Lauseker M et al (2009) Optimization of imatinib therapy by combination. 5 year survival and response results of the pilot phase of the randomized German CML Study IV. Blood 114:862","journal-title":"Blood"},{"key":"2782_CR23","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259","journal-title":"N Engl J Med"},{"key":"2782_CR24","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","volume":"115","author":"Saussele","year":"2010","unstructured":"Saussele S, Lauseker M, Gratwohl A et al (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115:1880\u20131885","journal-title":"Blood"},{"key":"2782_CR25","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"White","year":"2007","unstructured":"White DL, Saunders VA, Dang P et al (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:4064\u20134072","journal-title":"Blood"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-010-2782-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-010-2782-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-010-2782-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T13:04:34Z","timestamp":1592226274000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-010-2782-3"}},"subtitle":["Ein Beispiel f\u00fcr den Paradigmenwechsel in der H\u00e4matoonkologie"],"short-title":[],"issued":{"date-parts":[[2011,1,13]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["2782"],"URL":"https:\/\/doi.org\/10.1007\/s00108-010-2782-3","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,13]]}}}